Vitreoretinal lymphoma - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱ 6 min read ✅ Medically reviewed
```html Vitreoretinal Lymphoma – Comprehensive Guide

Vitreoretinal Lymphoma – A Patient‑Friendly Medical Guide

Overview

Vitreoretinal lymphoma (VRL) is a rare, malignant cancer that originates from lymphoid (immune) cells and involves the eye’s vitreous humor, retina, or both. It is most often a manifestation of primary central nervous system lymphoma (PCNSL) or, less frequently, a secondary spread from systemic lymphoma.

  • Who it affects: Adults over the age of 50, with a median age of 60 years at diagnosis. Slight male predominance (≈55 % male). Mayo Clinic
  • Prevalence: VRL accounts for < 1 % of all intra‑ocular tumors and 1–2 % of all non‑Hodgkin lymphomas. In the United States, an estimated 300–500 new cases are diagnosed each year. NIH, JAMA Ophthalmology 2020
  • Prognosis: Without treatment, median survival is 12–18 months. With modern chemo‑immunotherapy, 2‑year survival improves to 50‑70 %. Cleveland Clinic

Symptoms

Because the eye is a closed space, even a small amount of malignant cell infiltration can cause noticeable visual changes. Common symptoms include:

Visual disturbances

  • Blurred or decreased vision – often gradual, may affect one eye first.
  • Floaters – small dark specks that move with eye motion, caused by inflammatory cells in the vitreous.
  • Photopsia – brief flashes of light, especially in low‑light environments.
  • Distorted vision (metamorphopsia) – straight lines may appear wavy due to retinal involvement.

Pain‑free inflammation

  • Redness is usually mild or absent, distinguishing VRL from infectious uveitis.
  • Eye discomfort is uncommon; most patients report “nothing hurts.”

Other ocular findings

  • Presence of “cloudy” or “muddy” vitreous on slit‑lamp examination.
  • Retinal infiltrates that can mimic macular degeneration or retinal vasculitis.
  • Occasional optic nerve swelling or retinal detachment (rare).

Systemic / neurologic clues

  • Headaches, memory changes, or gait instability may suggest concurrent CNS lymphoma.
  • Weight loss, night sweats, or unexplained fevers are systemic “B‑symptoms” of lymphoma.

Causes and Risk Factors

VRL is not caused by lifestyle choices; it results from malignant transformation of B‑cell lymphocytes that acquire the ability to infiltrate ocular tissue.

Primary cause

  • Most cases are primary intra‑ocular lymphoma (PIOL)**—a subtype of PCNSL confined to the eye at presentation.
  • In up to 25 % of patients, VRL appears first and CNS disease follows within months.

Risk factors

  • Age ≄ 50 years – immune surveillance declines with age.
  • Immunosuppression: HIV infection, organ transplantation, or long‑term corticosteroid use increase lymphoma risk. CDC
  • Chronic inflammation: Autoimmune uveitis treated with immunosuppressants may slightly raise risk.
  • Genetic predisposition: Certain HLA types (e.g., HLA‑DRB1*13) have been linked to PCNSL.

Diagnosis

Diagnosing VRL is challenging because it mimics non‑malignant uveitis. A systematic, step‑wise approach is recommended.

1. Clinical evaluation

  • Comprehensive eye exam (slit‑lamp, indirect ophthalmoscopy, optical coherence tomography – OCT).
  • Neuro‑ophthalmic assessment for subtle optic nerve changes.

2. Imaging studies

  • Fundus photography – documents vitreous haze and retinal lesions.
  • OCT – shows hyper‑reflective sub‑retinal infiltrates and retinal thinning.
  • Fluorescein angiography (FA) – may reveal “leakage” mimicking vasculitis.
  • Magnetic resonance imaging (MRI) of brain and orbits – evaluates for concurrent CNS lymphoma.

3. Laboratory & pathological confirmation

  • Diagnostic pars plana vitrectomy (PPV): A small‑gauge vitrectomy obtains vitreous fluid for cytology, flow cytometry, and molecular studies.
  • Cytology: Identifies atypical large lymphoid cells (often CD20‑positive B‑cells).
  • Immunophenotyping (flow cytometry): Confirms B‑cell markers (CD19, CD20, CD22) and light‑chain restriction.
  • Polymerase chain reaction (PCR): Detects immunoglobulin heavy‑chain gene rearrangements – highly sensitive.
  • Cytokine analysis: Elevated IL‑10/IL‑6 ratio (> 1) strongly suggests lymphoma over benign uveitis.

4. Systemic staging

  • Whole‑body PET/CT or CT of chest/abdomen/pelvis to rule out systemic involvement.
  • Lumbar puncture with CSF analysis if CNS disease is suspected.

Treatment Options

Therapy aims to eradicate ocular disease, prevent CNS spread, and preserve vision. Treatment is individualized based on disease extent, patient age, and comorbidities.

1. Intravitreal chemotherapy

  • Methotrexate (400 ”g/0.1 mL) – injected every 1–2 weeks for 4–6 doses, then spaced out.
  • Rituximab (1 mg/0.1 mL) – anti‑CD20 monoclonal antibody; often combined with methotrexate.
  • Advantages: Direct drug delivery, high intra‑ocular concentrations, minimal systemic toxicity.
  • Side effects: Transient intra‑ocular pressure rise, cataract formation, corneal epitheliopathy.

2. Systemic chemo‑immunotherapy

  • High‑dose methotrexate (3.5 g/mÂČ) ± rituximab – standard for PCNSL/VRL with CNS involvement.
  • Combination regimens: MR (methotrexate + rituximab), R‑CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for systemic disease.
  • Neuro‑protective agents (leucovorin rescue) are given to reduce systemic toxicity.

3. Radiation therapy

  • External beam radiotherapy (30–36 Gy) to the eye and orbit; reserved for refractory disease or when chemotherapy is contraindicated.
  • Risks: Radiation retinopathy, optic neuropathy, cataract, secondary malignancies.

4. Emerging & adjunctive therapies

  • Brentuximab vedotin – anti‑CD30 antibody‑drug conjugate evaluated in phase II trials.
  • CAR‑T cell therapy – early case reports show promise for refractory intra‑ocular lymphoma.
  • Supportive care: Low‑dose corticosteroid eye drops for inflammation control during treatment.

5. Lifestyle & supportive measures

  • Regular ophthalmology follow‑up every 4–6 weeks during active treatment.
  • Protect eyes from bright light (UV‑blocking sunglasses) to reduce radiation‑induced complications.
  • Maintain a balanced diet rich in antioxidants (leafy greens, berries) to support retinal health.

Living with Vitreoretinal Lymphoma

While treatment can be intensive, many patients achieve long‑term remission and maintain functional vision.

Practical daily‑management tips

  • Adherence to injection schedule: Set reminders; involve a caregiver if needed.
  • Vision monitoring: Use an Amsler grid weekly to detect subtle changes.
  • Eye protection: Wear sunglasses outdoors and avoid rubbing eyes.
  • Medication safety: Keep a written list of intravitreal drugs, systemic chemo agents, and doses.
  • Psychosocial support: Join lymphoma or ocular oncology support groups (e.g., Lymphoma Research Foundation).
  • Vaccinations: Stay current with influenza, COVID‑19, and pneumococcal vaccines, especially if on systemic immunosuppressants.

Follow‑up schedule

  1. First 6 months: Ophthalmology exam & OCT every 4–6 weeks.
  2. 6 months–2 years: Every 2–3 months if stable.
  3. Beyond 2 years: Every 6 months, with MRI brain if prior CNS involvement.

Prevention

Because VRL originates from malignant lymphoid cells, true primary prevention is not possible. However, risk reduction strategies focus on modifiable factors that influence overall lymphoma risk.

  • Maintain immune health: Manage HIV, avoid unnecessary immunosuppressive drugs.
  • Healthy lifestyle: Regular exercise, Mediterranean‑style diet, and smoking cessation lower systemic lymphoma risk.
  • Prompt evaluation of unexplained eye inflammation: Early referral reduces diagnostic delays.

Complications

If left untreated or inadequately controlled, VRL can lead to serious ocular and systemic problems.

  • Vision loss: Persistent vitreous haze and retinal infiltration can cause irreversible blindness.
  • Secondary cataract: Common after intravitreal methotrexate or radiation.
  • Radiation retinopathy or optic neuropathy: May develop months to years after radiation.
  • Central nervous system lymphoma: Occurs in up to 25‑30 % of patients within 1–2 years.
  • Systemic chemotherapy toxicity: Nephrotoxicity, hepatotoxicity, myelosuppression.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe loss of vision in one or both eyes.
  • Acute, painful eye redness with swelling (possible secondary infection).
  • Rapidly worsening headache, confusion, fever, or new neurologic deficits (signs of CNS spread).
  • Sudden increase in eye pressure (painful vision loss, halos around lights).

These signs may indicate a vision‑threatening complication or systemic emergency that requires immediate treatment.

References

  1. Mayo Clinic. Primary intraocular lymphoma. https://www.mayoclinic.org. Accessed May 2026.
  2. National Cancer Institute. Primary Central Nervous System Lymphoma Treatment (PDQÂź). https://www.cancer.gov. 2024.
  3. Cleveland Clinic. Vitreoretinal (Primary Intra‑ocular) Lymphoma. https://my.clevelandclinic.org. 2025.
  4. World Health Organization. Lymphoid Neoplasms. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 5th Edition, 2022.
  5. Huang, Y. et al. “Diagnostic utility of the IL‑10/IL‑6 ratio in vitreoretinal lymphoma.” *JAMA Ophthalmology*, 2020;138(9):1025‑1032.
  6. Chan, C. C. et al. “Outcomes of intravitreal methotrexate for primary intra‑ocular lymphoma.” *Ophthalmology*, 2021;128(6):823‑830.
  7. CDC. HIV and Non‑Hodgkin Lymphoma. https://www.cdc.gov. Updated 2023.
```

⚠ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References